{"entity":{"id":"nct07154706","kind":"trial","name":"Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)","aka":[],"tldr":"A phase 3 trial of Taletrectinib in non-small-cell lung cancer and small-cell lung cancer, run by Nuvation Bio Inc., now recruiting.","summary":"Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV) is a phase 3 interventional study registered as NCT07154706 by Nuvation Bio Inc., with 180 participants planned, started 2025-08-21 and due to reach its primary completion in 2030-08-30. Interventions recorded: Taletrectinib, Placebo. Conditions listed: Non-small Cell Lung Cancer (NSCLC). No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07154706","url":"https://clinicaltrials.gov/study/NCT07154706"}],"tags":["ctgov-ingest"],"related":[],"cancers":["nsclc","sclc"],"sections":[],"technologies":[],"targets":[],"drugs":["taletrectinib"],"companies":["nuvation-bio"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07154706","phase":"3","setting":"A Phase 3 Multicenter Double-blind Randomized Study of Taletrectinib Versus Placebo in Patients With ROS1-Fusion Positive Stage IB-IIIA Non-Small Cell Lung Cancer Who Have Undergone Complete Tumor Resection","sponsor":"Nuvation Bio Inc.","enrolled":180,"outcomes":[]},"route":"/trials/nct07154706/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"drug":[{"id":"taletrectinib","kind":"drug","name":"Taletrectinib","route":"/drugs/taletrectinib/"}],"company":[{"id":"nuvation-bio","kind":"company","name":"Nuvation Bio","route":"/companies/nuvation-bio/"}]}}